8-K: International Isotopes Rebrands as Radnostix, Inc.

International Isotopes Inc. has officially changed its corporate name to Radnostix, Inc., reflecting an expanded focus on healthcare-related radioisotopes and theranostics.

Summary

• International Isotopes Inc. filed a Certificate of Amendment in Texas on December 23, 2025, to change its corporate name to Radnostix, Inc.
• The board of directors approved the Name Change on October 21, 2025, and a majority of shareholders approved it by written consent on November 25, 2025.
• The rebranding reflects an expanded business focus from radiochemicals and non-medical radioisotopes (energy-sector) to a broader portfolio of radioisotope, theranostics, and related products, devices, and accessories, primarily for healthcare applications.
• The company's common stock will continue to trade under the current ticker symbol INIS on the OTCQB marketplace.
• Shareholders are not required to take any action regarding their stock certificates as a result of the name change.
• A press release announcing the name change was issued on December 31, 2025.
• Existing brands such as Radqual, Radvent, Easyfill, Benchmark, and PhanQual will continue under the Radnostix, Inc. umbrella.
• The INIS branding will be re-utilized for segments focused on high energy sources, bulk radioisotopes, and stable isotopes.

Sentiment

Score: 7

Explanation: The name change and rebranding reflect a strategic pivot towards a growing and specialized segment of the healthcare industry (radioisotopes and theranostics), which is generally viewed as a positive long-term strategic alignment.

Positives

• The new name, Radnostix, Inc., better reflects the company's evolving strategic focus on radioisotopes and theranostics, particularly in healthcare applications.
• The company is expanding its product segments and strategic focus, indicating potential growth opportunities in the healthcare sector.
• Management team and commitment to customers and partners remain unchanged, ensuring continuity.
• The company manufactures and supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer.
• Provides contract manufacturing of various drug products and radioisotope API supply for 3rd party theranostics clients.
• Manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems, as well as industrial calibration standards under its RadQual brand.
• Manufactures Cobalt-60 sealed source products.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results, performance, or achievements to be materially different from those expressed or implied. Further details are available in the company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company believes Radnostix, Inc. better reflects its focus on radioisotopes and theranostics going forward, aiming to become the premiere industry partner in this space. Further information regarding a potential new ticker symbol will be announced in due course.

Management Comments

• "The name Radnostix better encapsulates our mission to become the premiere industry partner in the radioisotope & theranostics space. While our name is changing, our dedication to quality, innovation, and customer service and our strategic direction remain steadfast." Shahe Bagerdjian, President and Chief Executive Officer.

Industry Context

The strategic shift towards radioisotopes and theranostics, particularly in healthcare applications, aligns with a broader industry trend towards precision medicine and targeted therapies. This repositioning aims to capitalize on the increasing demand for specialized diagnostic and therapeutic radioisotopes in the medical field.

Corporate Governance

Stakeholder Impact

• Shareholders: No action required regarding stock certificates; potential for long-term value creation through strategic repositioning in a growing market; potential future ticker symbol change.
• Customers/Partners: Operations, management team, and commitment remain unchanged, ensuring continuity of service and relationships.

Next Steps

• Officially begin to rebrand all operations under the Radnostix name immediately.
• Announce further information regarding a potential new ticker symbol in due course.

Key Dates

Recommendation

The company's name change to Radnostix, Inc. signifies a strategic pivot towards the growing radioisotope and theranostics market within healthcare. While this repositioning is a positive long-term strategic move, the filing does not contain immediate financial results or specific forward-looking guidance that would warrant a strong buy or sell recommendation. Investors should hold and monitor future financial reports and operational updates to assess the tangible benefits of this strategic shift.

Keywords

Radnostix, International Isotopes, Name Change, Radioisotopes, Theranostics, Healthcare, Radiopharmaceuticals, Medical Devices, SEC Filing, 8-K, INIS